RELA (Ab-254) Antibody

What is RELA (Ab-254) Antibody and what does it detect?

RELA (Ab-254) Antibody is a polyclonal antibody that specifically recognizes and binds to endogenous levels of total NFkB-p65 protein. It targets a specific peptide sequence around amino acids 252-256 (F-R-T-P-P) derived from human NFkB-p65 . This antibody is useful in studying NF-kappa-B, a pleiotropic transcription factor involved in numerous biological processes including inflammation, immunity, differentiation, cell growth, tumorigenesis, and apoptosis .

What are the technical specifications of RELA (Ab-254) Antibody?

The RELA (Ab-254) Antibody has the following specifications:

• Host species: Rabbit

• Clonality: Polyclonal

• Species reactivity: Human, Mouse, Rat

• Applications: ELISA, IHC

• Concentration: 1.0mg/mL

• Buffer formulation: Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol

• Storage requirements: Store at -20°C or -80°C for long-term preservation; avoid repeated freeze-thaw cycles

How is the RELA (Ab-254) Antibody purified?

The antibody is produced by immunizing rabbits with synthetic peptide and KLH (Keyhole Limpet Hemocyanin) conjugates. It is subsequently purified through affinity-chromatography using epitope-specific peptides . This purification method ensures high specificity by isolating only those antibodies that recognize the target epitope, thereby minimizing cross-reactivity with other proteins.

What are the validated applications for RELA (Ab-254) Antibody?

The RELA (Ab-254) Antibody has been validated for the following applications:

• ELISA (Enzyme-Linked Immunosorbent Assay): For quantitative detection of NFkB-p65 in solution

• IHC (Immunohistochemistry): For localizing NFkB-p65 in tissue sections

The recommended dilution for IHC applications is 1:50-1:100 . When using this antibody in new experimental contexts or with different sample types, researchers should perform appropriate validation studies to determine optimal conditions.

How can researchers optimize the RELA (Ab-254) Antibody for immunohistochemistry protocols?

For optimal IHC results with RELA (Ab-254) Antibody:

• Fixation considerations:

  • For formalin-fixed paraffin-embedded tissues, ensure proper fixation times (typically 24-48 hours)

  • Consider antigen retrieval methods (heat-induced epitope retrieval in citrate buffer pH 6.0 or EDTA buffer pH 8.0)

• Blocking optimization:

  • Use 5-10% normal serum from the same species as the secondary antibody

  • Include 0.1-0.3% Triton X-100 for nuclear antigens like NFkB-p65

• Antibody incubation:

  • Start with the recommended dilution (1:50-1:100)

  • Optimize incubation time and temperature (typically overnight at 4°C or 1-2 hours at room temperature)

  • Consider using a humidity chamber to prevent tissue drying

• Detection system:

  • Use an appropriate detection system compatible with rabbit primary antibodies

  • Include proper negative controls (omitting primary antibody) and positive controls (tissues known to express NFkB-p65)

What controls should be included when using RELA (Ab-254) Antibody in research studies?

When designing experiments using RELA (Ab-254) Antibody, include the following controls:

• Positive control:

  • Tissue or cell samples known to express NFkB-p65 (e.g., activated lymphocytes, tissues with inflammation)

  • Recombinant NFkB-p65 protein for ELISA applications

• Negative controls:

  • Tissue samples processed identically but omitting the primary antibody

  • Samples known not to express NFkB-p65

  • Pre-absorption control using the immunizing peptide

• Isotype control:

  • Non-specific rabbit IgG at the same concentration as the primary antibody

Including these controls helps validate specificity and allows for accurate interpretation of results while controlling for potential background or non-specific binding.

How can RELA (Ab-254) Antibody be used to study NF-κB pathway activation in inflammatory conditions?

The RELA (Ab-254) Antibody can be utilized for studying NF-κB pathway activation through several methodological approaches:

• Immunohistochemistry/Immunofluorescence:

  • Track nuclear translocation of p65 (a hallmark of NF-κB activation)

  • Quantify the percentage of cells showing nuclear p65 staining

  • Compare nuclear/cytoplasmic staining ratios between treatment groups

• Combination with phospho-specific antibodies:

  • Use alongside antibodies that detect phosphorylated p65 (particularly at Ser536)

  • This combination allows discrimination between total p65 (detected by RELA Ab-254) and the activated form

• Sequential experimental design:

  • Stimulate cells with inflammatory mediators (TNF-α, IL-1β, LPS)

  • Collect samples at multiple time points (15 min, 30 min, 1h, 2h, 4h)

  • Use RELA (Ab-254) Antibody to track p65 localization over time

  • Correlate with downstream gene expression changes

• Inhibitor studies:

  • Pre-treat cells with NF-κB pathway inhibitors

  • Measure the impact on p65 nuclear translocation using the antibody

  • Establish dose-response relationships for potential therapeutic agents

This approach provides detailed insights into inflammatory signaling dynamics beyond simple presence/absence determinations.

What are the techniques for validating RELA (Ab-254) Antibody specificity in research contexts?

Comprehensive validation of RELA (Ab-254) Antibody specificity involves multiple complementary approaches:

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunizing peptide (aa.252-256, F-R-T-P-P)

  • Apply to identical samples in parallel with the antibody alone

  • Specific signals should be significantly reduced or eliminated

• Genetic knockdown validation:

  • Use siRNA or CRISPR-Cas9 to deplete RELA/p65 expression

  • Compare antibody signals between control and knockdown samples

  • Quantify the degree of signal reduction relative to knockdown efficiency

• Western blot analysis:

  • Confirm the molecular weight of the detected protein (~65 kDa)

  • Assess for presence/absence of non-specific bands

  • Compare migration patterns across different sample types

• Orthogonal detection methods:

  • Correlate antibody results with alternative detection methods (e.g., RT-PCR for mRNA levels)

  • Use mass spectrometry to confirm identity of immunoprecipitated proteins

• Cross-species reactivity testing:

  • Systematically test reactivity across human, mouse and rat samples

  • Sequence alignment of the epitope region to predict potential cross-reactivity

Proper validation ensures confidence in experimental results and facilitates accurate data interpretation.

How can RELA (Ab-254) Antibody be integrated into multiplexed experimental systems?

Integrating RELA (Ab-254) Antibody into multiplexed experiments requires careful consideration of several methodological factors:

• Multiplex immunofluorescence approach:

  • Combine with antibodies targeting other NF-κB pathway components (IκBα, IKK)

  • Use spectrally distinct fluorophores for each target

  • Include nuclear counterstain (DAPI) for localization analysis

  • Apply spectral unmixing to minimize fluorophore bleed-through

• Sequential immunohistochemistry:

  • Use tyramide signal amplification to allow multiple antibody stripping cycles

  • Start with the RELA (Ab-254) Antibody (typically at 1:100 dilution)

  • Follow with other antibodies of interest after appropriate stripping protocols

  • Consider automated systems for reproducibility

• Flow cytometry applications:

  • Optimize fixation and permeabilization protocols for nuclear proteins

  • Determine appropriate antibody concentration through titration (typically start at 0.5-1 μg per test)

  • Include appropriate isotype controls and single-stain controls

  • Consider phospho-flow approaches for activation status

• Mass cytometry (CyTOF) integration:

  • Conjugate RELA (Ab-254) Antibody with appropriate metal isotopes

  • Validate metal-conjugated antibody against unconjugated version

  • Include appropriate compensation controls

• Data integration strategies:

  • Use computational methods to correlate RELA/p65 status with other measured parameters

  • Apply dimensionality reduction techniques (tSNE, UMAP) for visualization

  • Consider machine learning approaches for pattern recognition

This multiplex approach enables comprehensive pathway analysis within the context of complex biological systems.

How should researchers address potential cross-reactivity concerns with RELA (Ab-254) Antibody?

When addressing potential cross-reactivity:

• Epitope sequence analysis:

  • Perform BLAST searches of the immunizing peptide sequence (F-R-T-P-P)

  • Identify proteins with similar sequences that might cross-react

  • Generate a prioritized list of potential cross-reactants

• Testing methodology:

  • Use cell lines with known expression profiles of RELA and related proteins

  • Compare results across multiple detection methods (IHC, Western blot, ELISA)

  • Include selective gene knockdown controls for related proteins

• Blocking strategy:

  • Implement more stringent blocking protocols (5% BSA + 5% normal serum)

  • Consider pre-adsorption with related proteins if specific cross-reactivity is suspected

  • Optimize antibody concentration to minimize non-specific binding

• Orthogonal validation:

  • Compare results with other commercially available anti-RELA antibodies targeting different epitopes

  • Correlate antibody results with genetic assays (RT-PCR, RNA-seq)

This systematic approach helps distinguish specific signals from potential cross-reactivity, especially in complex experimental systems.

What strategies can address weak or inconsistent signals when using RELA (Ab-254) Antibody in immunohistochemistry?

For weak or inconsistent IHC signals:

• Antigen retrieval optimization:

  • Compare heat-induced epitope retrieval methods:

    • Citrate buffer (pH 6.0)

    • EDTA buffer (pH 8.0)

    • Tris-EDTA (pH 9.0)

  • Test different retrieval durations (10-30 minutes)

  • Compare microwave, pressure cooker, and water bath methods

• Signal amplification techniques:

  • Implement tyramide signal amplification (TSA)

  • Consider polymer-based detection systems

  • Optimize chromogen development time

• Fixation considerations:

  • Test different fixation protocols (duration, fixative type)

  • Consider post-fixation processing effects on epitope accessibility

  • For frozen sections, optimize fixation timing

• Antibody incubation parameters:

  • Extend primary antibody incubation (overnight at 4°C)

  • Test higher antibody concentrations (1:25 - 1:50 range)

  • Optimize incubation temperature

• Sample handling:

  • Minimize time between sectioning and staining

  • Ensure consistent section thickness

  • Address potential tissue autofluorescence

Maintaining a systematic testing approach with detailed documentation facilitates protocol optimization and ensures reproducible results.

How do different sample preparation methods affect the performance of RELA (Ab-254) Antibody?

Sample preparation significantly impacts antibody performance:

Different experimental questions may require specific sample preparation approaches. For nuclear proteins like RELA/p65, particular attention must be paid to nuclear permeabilization and fixation methods to ensure antibody accessibility to the target epitope.

How does RELA (Ab-254) Antibody compare with other antibodies targeting different epitopes of the NFkB-p65 protein?

The RELA (Ab-254) Antibody targets a specific epitope (aa.252-256, F-R-T-P-P) that offers distinct advantages and limitations compared to antibodies targeting other regions:

For comprehensive pathway analysis, researchers often employ multiple antibodies targeting different epitopes or modifications in parallel experimental streams.

What are the methodological considerations when using RELA (Ab-254) Antibody to investigate nuclear translocation dynamics of NFkB-p65?

Investigating NFkB-p65 nuclear translocation requires specific methodological approaches:

• Temporal resolution considerations:

  • Design time-course experiments (5, 15, 30, 60, 120 minutes post-stimulation)

  • Use synchronized cell populations when possible

  • Consider live-cell imaging for real-time dynamics

• Subcellular fractionation protocol:

  • Optimize nuclear/cytoplasmic extraction buffers

  • Verify fraction purity using compartment-specific markers:

    • Nuclear: Lamin B1, Histone H3

    • Cytoplasmic: GAPDH, α-tubulin

  • Quantify RELA/p65 in each fraction by Western blot or ELISA

• Immunofluorescence quantification:

  • Apply nuclear/cytoplasmic intensity ratio analysis

  • Use automated image analysis algorithms

  • Implement cell-by-cell analysis rather than whole-field measurements

  • Establish objective nuclear translocation thresholds

• Stimulus-specific considerations:

  • TNF-α: Rapid translocation (peak at 15-30 minutes)

  • LPS: Delayed response (peak at 30-60 minutes)

  • IL-1β: Intermediate kinetics

  • Calibrate sampling time points to specific stimulus

• Data normalization approaches:

  • Calculate nuclear/cytoplasmic ratios

  • Use area under the curve (AUC) for time-course experiments

  • Apply appropriate statistical tests for time-series data

This methodological framework enables detailed characterization of NFkB pathway activation dynamics in response to various stimuli.

How can researchers integrate RELA (Ab-254) Antibody data with other omics approaches for comprehensive pathway analysis?

Integrating antibody-based data with multi-omics approaches requires sophisticated experimental design and data analysis:

• Multi-omics experimental design:

  • Parallel sample processing for antibody-based detection and omics analysis

  • Synchronized time points across all platforms

  • Include appropriate controls for each methodology

• Integration with transcriptomics:

  • Correlate RELA/p65 nuclear translocation with expression of known NF-κB target genes

  • Identify gene sets showing temporal correlation with p65 activation

  • Implement gene set enrichment analysis (GSEA) to identify affected pathways

• Integration with phosphoproteomics:

  • Map phosphorylation events in the NF-κB signaling cascade

  • Correlate with RELA/p65 localization data

  • Identify feedback mechanisms and cross-talk with other pathways

• ChIP-seq correlation:

  • Compare RELA (Ab-254) Antibody IHC/IF results with ChIP-seq data on p65 binding sites

  • Integrate with chromatin accessibility data (ATAC-seq)

  • Correlate binding events with gene expression changes

• Computational analysis approaches:

  • Apply network analysis to construct comprehensive pathway models

  • Use machine learning to identify patterns across multi-omics datasets

  • Implement Bayesian networks to infer causal relationships

• Visualization strategies:

  • Develop integrated heatmaps showing antibody-based quantification alongside omics data

  • Use pathway visualization tools that incorporate multiple data types

  • Implement dimensional reduction techniques for multi-parameter analysis

This integrated approach provides systems-level insights beyond what can be achieved with antibody-based detection alone.

What are the critical factors in validating lot-to-lot consistency of RELA (Ab-254) Antibody for longitudinal research projects?

Ensuring lot-to-lot consistency is crucial for research continuity:

• Standardized validation protocols:

  • Develop a panel of reference samples representing range of expression levels

  • Establish quantitative performance metrics:

    • Signal-to-noise ratio in IHC/IF

    • EC50 values in ELISA

    • Band intensity in Western blot

  • Document acceptance criteria for each application

• Side-by-side comparison methodology:

  • Test new and previous lots in parallel

  • Use the same samples, reagents, and conditions

  • Quantify relative performance using digital image analysis

  • Apply statistical tests to assess equivalence

• Reference standard approach:

  • Maintain aliquots of a reference lot for comparative testing

  • Create standard curves for quantitative applications

  • Establish correction factors if necessary

• Documentation system:

  • Maintain detailed records of validation results

  • Document any adjustment factors needed for data normalization

  • Track antibody performance over time

• Long-term storage considerations:

  • Aliquot antibodies to minimize freeze-thaw cycles

  • Monitor storage conditions (temperature logs)

  • Implement regular quality control testing of stored aliquots

This systematic approach helps maintain data consistency and reliability across extended research projects.

How can researchers determine the appropriate antibody concentration for specific experimental systems?

Determining optimal antibody concentration requires systematic titration:

• Initial titration approach:

  • Prepare serial dilutions (typically 1:25, 1:50, 1:100, 1:200, 1:500, 1:1000)

  • Use positive control samples with known expression

  • Include appropriate negative controls

  • Test under identical conditions

• Evaluation criteria:

  • Signal-to-noise ratio (target signal vs. background)

  • Dose-response relationship

  • Minimal concentration yielding reproducible results

  • Signal saturation threshold

• Application-specific considerations:

  • IHC/IF: Start with manufacturer's recommendation (1:50-1:100)

  • Western blot: Typically higher dilution (1:500-1:1000)

  • ELISA: Requires careful optimization based on capture vs. detection role

• Sample-specific adjustments:

  • Fresh vs. archived tissues may require different concentrations

  • Consider tissue-specific factors (fixation, autofluorescence)

  • Cell type-specific expression levels may necessitate adjustment

• Quantification methods:

  • Use digital image analysis for objective assessment

  • Calculate staining intensity and percentage of positive cells

  • Generate titration curves to identify optimal concentration range

The goal is to identify the minimum antibody concentration that provides maximum specific signal with minimal background, optimizing both experimental quality and resource utilization.

How might RELA (Ab-254) Antibody be applied in emerging single-cell analysis technologies?

The application of RELA (Ab-254) Antibody in single-cell technologies presents innovative research opportunities:

• Single-cell proteomics integration:

  • Adaptation for mass cytometry (CyTOF) through metal conjugation

  • Application in microfluidic antibody-based single-cell proteomics

  • Integration with single-cell Western blot technologies

  • Development of compatible protocols for CITE-seq (cellular indexing of transcriptomes and epitopes)

• Spatial transcriptomics correlation:

  • Combined immunofluorescence with RELA (Ab-254) Antibody and in situ transcriptomics

  • Correlation of RELA/p65 localization with spatial expression of NF-κB target genes

  • Development of multiplexed imaging approaches combining protein and RNA detection

• Live-cell antibody applications:

  • Development of cell-permeable antibody derivatives

  • Integration with optogenetic systems to monitor real-time pathway dynamics

  • Application in microfluidic single-cell analysis platforms

• Methodological challenges to address:

  • Optimizing fixation and permeabilization for nuclear factor detection

  • Developing compatible barcoding strategies for high-throughput analysis

  • Minimizing antibody-induced perturbations in single-cell systems

• Analytical approaches:

  • AI-assisted image analysis for heterogeneity assessment

  • Correlation of protein data with single-cell transcriptomics

  • Trajectory analysis of NFkB pathway activation at single-cell resolution

These approaches would enable unprecedented insights into cell-to-cell variability in NFkB signaling responses.

What are the considerations for using RELA (Ab-254) Antibody in conjunction with emerging proximity ligation techniques?

Proximity ligation assays (PLAs) offer powerful tools for studying protein-protein interactions:

• Assay design considerations:

  • Combine RELA (Ab-254) Antibody with antibodies against potential interaction partners

  • Select PLA probes compatible with rabbit primary antibodies

  • Optimize probe concentrations and incubation conditions

  • Consider steric constraints that may affect probe hybridization

• Potential research applications:

  • Map RELA/p65 interactions with other transcription factors

  • Investigate dynamic assembly/disassembly of NFkB complexes

  • Study post-translational modifications through modified PLA approaches

  • Analyze spatial distribution of protein interactions in tissue contexts

• Technical optimization strategies:

  • Test multiple fixation protocols to preserve interactions while allowing antibody access

  • Optimize permeabilization to balance nuclear access with interaction preservation

  • Develop quantification methods for PLA signals

  • Implement appropriate controls to validate interaction specificity

• Advanced PLA variations:

  • In situ PLA for tissue section analysis

  • Triple PLA to detect three-component complexes

  • Dynamic PLA for temporal resolution of interactions

  • Combination with FRET for additional validation

This approach would enable detailed mapping of the RELA/p65 interactome under various physiological and pathological conditions.